Status: Recruiting
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.
Participants needed: 17
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Leucid BioUpdated: Sep 3, 2025Locations: 2
Eligibility criteria
Histologically and/or cytologically confirmed solid tumour. [+20]
Subjects with HIV-1, HIV-2, HTLV-1, HTLV-2, active Hepatitis B, active Hepatitis... [+13]